Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in